Here, using ART-treated, SIV-infected rhesus macaques, we show that CTLA-4 + PD-1 À memory CD4 + T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut, and contained replication-competent and infectious virus. In contrast to PD-1 + Tfh cells, SIV-enriched CTLA-4 + PD-1 À CD4 + T cells were found outside the B cell follicle of the LN, predicted the size of the persistent viral reservoir during ART, and significantly increased their contribution to the SIV reservoir with prolonged ART-mediated viral suppression. We have shown that CTLA-4 + PD-1 À memory CD4 + T cells are a previously unrecognized component of the SIV and HIV reservoir that should be therapeutically targeted for a functional HIV-1 cure.
INTRODUCTION
The ability of antiretroviral therapy (ART) to effectively suppress HIV-1 replication has dramatically reduced HIV morbidity and mortality (Bhaskaran et al., 2008; Cooper, 2008) . Despite this success, HIV-infected individuals must remain on ART for their lifetime due to the persistence of latently infected cells containing transcriptionally silent, integrated provirus, which allows them to evade immune detection (Chun et al., 1997a (Chun et al., , 1997b Finzi et al., 1997 Finzi et al., , 1999 Wong et al., 1997) . A fraction of these latently infected cells contain proviruses that are replication competent, constituting the latent viral reservoir that is responsible for the rebound of viremia upon treatment interruption Davey et al., 1999) . Therefore, strategies that target and eliminate latently infected cells are critically needed to achieve a functional cure for HIV. Identifying cellular subsets that preferentially harbor proviral DNA may facilitate the specific targeting of latent reservoirs. Resting memory CD4 + T cells are a well-characterized cellular reservoir, with numerous data suggesting the enrichment of proviral DNA within central, transitional, effector, and stem cell memory cells (Buzon et al., 2014; Chomont et al., 2009; Soriano-Sarabia et al., 2014) ; however, even among these memory subpopulations, there is a diversity of functional CD4 + T cell subsets, characterized by their distinct signature cytokines and immunological properties. Additionally, these subsets of memory CD4 + T cells are highly heterogeneous in their expression of surface markers, thus necessitating the identification of additional markers that more strictly define latently infected cells.
Recently, Banga et al. (2016) demonstrated that CD4 + T cells expressing programmed cell death protein-1 (PD-1) in lymph nodes (LN), which are largely composed of follicular helper T cells (Tfh), constitute an important source of persistent replicationcompetent virus in ART-treated, aviremic individuals (Banga et al., 2016) . In that study, the contribution of PD-1 + CD4 + T cells to the persistent reservoir progressively decreased with increased length of ART; this finding suggests that other cell subsets, apart from PD-1 + Tfh cells, may contribute to the magnitude of the pool of latently infected cells. In addition to PD-1, other co-inhibitory receptors (co-IRs) could maintain CD4 + T cells in a resting state (Kassu et al., 2010; Wherry, 2011) . Virus-specific CD4 + T cells upregulate multiple co-IRs, including PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T cell Ig domain and mucin domain 3 (TIM-3), in the setting of HIV and SIV infection (D'Souza et al., 2007; Jones et al., 2008; Kassu et al., 2010; Kaufmann et al., 2007) . Consistent with this model, Fromentin et al. (2016) showed that CD4 + T cells co-expressing three co-IRs (PD-1, TIGIT, and LAG-3) from the blood of ART-suppressed, HIV-infected individuals are enriched in proviral DNA when compared to subsets that included a single co-IR (Fromentin et al., 2016) . Using ART-treated, SIV-infected rhesus macaques (RMs) 
RESULTS

Expression of CTLA-4 Defines a Unique Subset of Virally Enriched CD4 + T Cells during ART in Multiple Tissues of SIV-Infected RMs
Ten RMs were infected intravenously with SIV mac251 ( Figure 1A ) and, at 52 days after infection, treated with ART (PMPA, FTC, raltegravir, and ritonavir-boosted darunavir; Table S1 ) for up to 14 months. RKa13 experienced rapid disease progression and was euthanized 10 days into ART. Overall, the combined ART regimen was effective in suppressing plasma viremia (>99.94% reduction from pre-ART, Figure S1A ), with 7 of 9 RMs demonstrating durable virus suppression by 290 days of ART with a single viral blip in only one of these animals. The two RMs with the highest pre-ART viral loads similarly had undetectable viremia after 288 and 317 days of ART, though both showed two viral blips (<500 copies/mL). At necropsy, 8 of 9 RMs had undetectable viral loads for an average of 125 ± 76 days, thus ensuring that measurements of cell-associated SIV DNA were performed in the absence of measurable, ongoing viral replication in plasma ( Figure 1B ). Consistent with HIV-infected humans (Autran et al., 1997; Kaufmann et al., 2000) , ART successfully elevated both CD4 + T cell frequencies ( Figure 1C ) and absolute counts (data not shown) in the blood and tissues of the SIV-infected RMs, although to frequencies that were significantly lower compared to pre-infection ( Figure 1C ). The efficacy of ART in suppressing viral replication was also evident in tissues, with a 61.6% reduction in the amount of SIV DNA found in LN as compared to pre-ART (Figures S1B and S1C). T cell homeostatic proliferation, which has been shown to be a major mechanism involved in HIV persistence, can induce the expression of several co-IRs such as PD-1, CTLA-4, and others (Chomont et al., 2009; Hatano et al., 2013) . To define the contribution of memory T cells expressing these co-IRs to the pool of latently infected cells as well as to identify their anatomic localization, we measured cell-associated SIVGAG DNA in CD95 + memory CD4 + T cells sorted based on their expression of coIRs ( Figure S2 ) from the blood, LN, spleen, and gut after a minimum of 3 months (and up to 7 months) following their first undetectable viral load. Although CTLA-4 functions as an inhibitory receptor through its engagement on the outer cell surface with its ligands CD80 and CD86, it is located primarily in endosomal vesicles from where it cycles continuously to and from the cell surface; for this reason, intracellular CTLA-4 expression is routinely used to measure accumulation and expression of CTLA-4 molecules (Linsley et al., 1996; Read et al., 2000; Teft et al., 2006) . Since cell permeabilization was incompatible with several analyses, we performed enhanced surface staining (ESS; see STAR Methods) to visualize surface CTLA-4 prior to sorting based on its expression. ESS captures rapidly upregulated surface CTLA-4 expression and reflects the amounts of intracellular CTLA-4 prior to stimulation, as previously shown (Kaufmann et al., 2007) ; we confirmed these observations by comparing ex vivo surface, ex vivo intracellular (ICS), and ESS staining (Figure S3) . Of note, this short stimulation does not affect the kinetics and frequencies of cells expressing PD-1 ( Figure S4 Figure 1E ). The increased viral content was specific for SIV DNA, since CTLA-4 + PD-1 À T cells harbored comparable (in the spleen) or lower (in LN and gut) amounts of SIV RNA than CTLA-4 À cells ( Figure S5 ). Amounts of SIV DNA did not differ between TIM-3 + and TIM-3 À populations within each CTLA-4-and PD-1-expressing subset (data not shown), confirming previous findings (Fromentin et al., 2016) . These results demonstrate that CTLA-4 + PD-1 À cells constitute a subset of memory CD4 + T cells enriched in viral DNA that persist during ART-mediated viral suppression in several lymphoid tissues.
CTLA-4
+ PD-1 -CD4 + T Cells Include a High Frequency of Regulatory T Cells CTLA-4 is one of the markers that defines regulatory T (Treg) cells (Read et al., 2000; Wing et al., 2008) ; hence, we investigated in ex vivo conditions the overlap between the above defined CTLA-4 + PD-1 À T cells and CTLA-4 + Treg cells ( Figure 2A Figure 2B ; Anderson et al., 2008; Seddiki et al., 2006 These markers include latency-associated peptide (Chen et al., 2008) , the transcription factor Helios (Baine et al., 2013; Ross et al., 2014) , the plasma membrane protein CD39 (Borsellino et al., 2007; Gu et al., 2017) , and the chemokine receptor CCR6 (Kitamura et al., 2010; Xu et al., 2010) (E) Cell-associated SIVGAG DNA was quantified from CTLA-4 and PD-1-sorted subsets of 9 ART-treated, SIV-infected RMs at least 3 months following the first undetectable viral load (163 ± 42 days). Data from subsets with fewer than 10,000 sorted cells were excluded when undetectable. Sample averages are indicated by the horizontal bar on each graph (±SEM), and t tests were used to compare amounts of DNA between subsets (P, PD-1; C, CTLA-4). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Please also see Figure S2 . Recent reports have demonstrated that Tfh cells harbor heightened amounts of HIV-1 DNA in the LN of ART-suppressed individuals (Banga et al., 2016) and that productive persistent SIV infection in elite controller RMs, but not typical progressors, is markedly restricted to the Tfh subset in the B cell follicle (Fukazawa et al., 2015) . In line with these reports, we identified LN Tfh cells phenotypically as CXCR5 + PD-1 hi memory CD4 + T cells and functionally by their production of IL-21 (Figures 2C and 2E; Chtanova et al., 2004; Haynes et al., 2007; Petrovas et al., 2012 Figure 2F ). Altogether, these results highlight the fact that two functional T helper cell subsets, i.e., Treg cells and Tfh cells, are targeted by SIV to establish viral persistence.
+ PD-1 -T Cells Enriched in Virus Are Localized outside the Lymph Node Follicle and Contribute to Viral Persistence during ART-Mediated Viral Suppression We used an in situ hybridization assay that combines the detection of viral DNA (vDNA) in fixed tissue sections with phenotypic analysis using immunofluorescence and confocal microscopy (Deleage et al., 2016) . This approach allowed us to determine the cellular and anatomic localization of SIV DNA in the LN of RMs ( Figure 3A ). Prior to ART initiation, vDNA in the T cell zone (TCZ) was found predominantly in CTLA-4 + PD-1 À cells ( Figure 3B ), although the majority of to the persistent SIV reservoir, we measured the production of replication-competent virus in these cells using a modified viral outgrowth assay previously described for SIV infection (Micci et al., 2015) . Figure 4A ). A 6-log exponential increase in SIV RNA was found in the co-culture supernatants of both subsets by day 35 ( Figure 4B ); with the amount of SIV RNA ranging between 10 8 and 10 9 in both CTLA-4 + PD-1 + and CTLA-4 + PD-1 À cells, we could not identify a statistically significant difference between these two subsets. Finally, supernatants collected from the VOA assay from 4 RMs were spiked on CEMx174 cells to determine the presence of infectious virus. In all 4 RMs, supernatants collected from the CTLA-4 + PD-1 À cells (as well as from the PD-1 + CTLA-4 + , data not shown) infected a high frequency of CEMx174 cells already at day 7 of culture ( Figure 4C ). Averaged data are presented as the mean ± SEM, and ANOVAs using Tukey's adjustment for multiple comparisons were used to compare differences between subsets. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Please also see Figure S6 .
Altogether, these results demonstrate that CTLA-4 We next tested the hypothesis that the frequencies of CTLA-4 + PD-1 À memory CD4 + T cells in the LN at acute infection could predict SIV persistence at later time points on ART. We found that the frequencies of CTLA-4 + PD-1 À memory CD4 + T cells at peak SIV infection correlated with the amount of SIV DNA (by ddPCR) within memory CD4 + ( Figure 5C ) and memory PD- 15.6 months (Table S2) . Consistent with the data generated in RMs, we identified HIV DNA + CD4 + T cells in the TCZ and found that the vast majority of these cells (72.9% ± 5.8%) express CTLA-4 + PD-1 À ( Figures 7A and 7B ). CTLA-4 T cells (Kaufmann et al., 2007; Paris et al., 2015) , which are preferential targets for HIV (Douek et al., 2002) . The enrichment of CTLA-4 + PD-1 À memory CD4 + T cells may also arise from their increased expression of molecules that will confer long-term survival (Riou et al., 2007) . Indeed, we found higher concentrations which support an increased persistence of this subset that preferentially harbors viral DNA. Others have also shown that Treg cells can resist apoptosis (Pandiyan et al., 2004) . Notably, Bach2, which has been previously shown to promote the differentiation and survival of FoxP3 + Treg cells (Kim et al., 2014) , was found to be a frequent integration site for HIV (Maldarelli et al., 2014) , which is consistent with our model of increased infectivity and persistence of Treg cells. Previous studies have demonstrated that Tfh cells are highly enriched in HIV DNA in both viremic and aviremic individuals (Banga et al., 2016; Lindqvist et al., 2012; Perreau et al., 2013) . Consistent with these studies, we found that PD-1 + CTLA-4 + cells, the subset that contributes most to Tfh cells, were the dominant contributors to the viral DNA pool in the B cell follicle in the LN during ART; however, we also found persistent virus outside of the follicle in the TCZ in CTLA-4 + PD-1 À cells, which phenotypically overlap with Treg cells. Herein we reveal their high viral DNA content in multiple tissues, their localization outside the B cell follicle in lymphoid tissues, and their growing contribution to viral persistence during ART. These findings extend prior studies that showed higher amounts of HIV-1 DNA in Treg cells from the blood of ART-treated, HIV-infected individuals (Jiao et al., 2015; Tran et al., 2008 , 2015) . Moreover, CTLA-4 blockade has also been explored as a monotherapy in viremic, SIV-infected RMs, where its use was associated with increased viral reactivation (Cecchinato et al., 2008; Hryniewicz et al., 2006) . Importantly, a recent case report demonstrates the ability of ipilimumab (anti-CTLA-4 antibody) to increase cell-associated HIV-1 RNA in an ART-suppressed, HIV-infected melanoma patient (Wightman et al., 2015) . This case study, by revealing the impact of targeting extracellular CTLA-4, supports the capacity of immunotherapeutic blockades to bind this transiently expressed molecule. These studies also support the capacity of CTLA-4 blockade to target latently infected cells and facilitate reactivation of virus, two actions necessary for the elimination of the latent reservoir. Further studies are needed in non-human primates to determine whether CTLA-4 blockade, alone or combined with PD-1 blockade, is effective and well tolerated in reducing the viral reservoir.
In summary, our study identifies CTLA-4 + PD-1 À memory CD4 + T cells as a unique subset harboring replication-competent SIV DNA that persists outside the B cell follicle despite ART-mediated viral suppression. By demonstrating the phenotypic overlap between CTLA-4 + PD-1 À memory CD4 + T cells and Treg cells and the presence of these cells in ART-treated, HIV-infected subjects, our results highlight that HIV is able to establish and maintain viral persistence through the specific targeting of another CD4 + T cell subset critical for the regulation of the adaptive immune system, in addition to PD-1 + Tfh cells.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
AUTHOR CONTRIBUTIONS
C.S.M., G.S., R.-P.S., and M.P. conceived the study; C.S.M., J.H., S.P., E.S.R., and S.J. performed sample collection and processing; C.D. and J.D.E. performed DNAScope analyses; C.S.M., L.K.-C., S.P.R., C.B., J.H., and L.M. performed cell survival phenotyping and viral outgrowth assays; K.E. performed statistical analysis; V.M. provided human specimens; and C.S.M., J.D.E., R.B., R.-P.S., and M.P. wrote the manuscript with inputs from all authors.
ACKNOWLEDGMENTS
We thank Stephanie Ehnert, Christopher Souder, and all the animal care and veterinary staff at the YNPRC, as well as Barbara Cervasi at the Emory Flow Cytometry Core. We also thank David Favre and Shari Gordon at GSK and David Margolis at UNC Chapel Hill for helpful discussion; Mathias Lichterfeld and Sean Harrington of the Ragon Institute for technical assistance; and Romas Geleziunas (Gilead), Guenter Kraus (Johnson & Johnson), and Daria Hazuda (Merck) for supplying the antiretroviral drugs. The SIVmac251 used to infect the RMs was kindly provided by Chris Miller. The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID: 174xCEM Cells from Dr. Peter Cresswell. M.P. is supported by the NIAID, NIH under award numbers 104278, 116379, 116171, and 110334 and by amfAR under award numbers 109354-59-RGRL. This work was also supported by ORIP/OD P51OD011132 (to the YNPRC), P30AI50409 (to the Emory CFAR), and in part with federal funds from the National Cancer Institute (NIH Contract HHSN261200800001E). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Autran, B., Carcelain, G., Li, T.S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré , P., and Leibowitch, J. (1997) . Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116.
Baine, I., Basu, S., Ames, R., Sellers, R.S., and Macian, F. (2013) . Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J. Immunol. 190, 1008 Immunol. 190, -1016 Banga, R., Procopio, F.A., Noto, A., Pollakis, G., Cavassini, M., Ohmiti, K., Corpataux, J.M., de Leval, L., Pantaleo, G., and Perreau, M. (2016) . PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754-761.
Beyer, M., Thabet, Y., M€ uller, R.U., Sadlon, T., Classen, S., Lahl, K., Basu, S., Zhou, X., Bailey-Bucktrout, S.L., Krebs, W., et al. (2011) . Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat. Immunol. 12, 898-907.
Bhaskaran, K., Hamouda, O., Sannes, M., Boufassa, F., Johnson, A.M., Lambert, P.C., and Porter, K.; CASCADE Collaboration (2008) . Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300, 51-59. 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mirko Paiardini (mirko.paiardini@emory.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Study Approval
All animal experimentations were conducted following guidelines established by the Animal Welfare Act and the NIH for housing and care of laboratory animals and performed in accordance with Institutional regulations after review and approval by the Institutional Animal Care and Usage Committees (IACUC; Permit number: 2002089) at the Yerkes National Primate Research Center (YNPRC). Anesthesia was administered prior to performing any procedure, and proper steps were taken to minimize the suffering of the animals in this study.
Patient population
Six HIV-seropositive subjects on suppressive ART for an average of 37.8 months (Table S2) were consented for a study approved by the Emory University Institutional Review Board. Individuals were receiving various combination antiretroviral regimens containing nucleoside reverse transcriptase inhibitors, a protease inhibitor, and/or integrase inhibitor. All subjects had undetectable viremia for at least 15.6 months (limit of detection: 50 copies/mL) before undergoing elective lymph node (LN) biopsies. LN sections were formalin-fixed and paraffin-embedded prior to performing DNAscope analysis (see below).
METHOD DETAILS
Animals, SIV-infection, and antiretroviral therapy Ten female Indian rhesus macaques (RMs; Macaca mulatta), all housed at the Yerkes National Primate Research Center, Atlanta, GA, were included in this study. All RMs were HLA*B07 -and HLA*B17 -with the following being HLA*A01 + : RSz12, RLr10, and RZm11. Prior to study assignment, all RMs are screen for SIV, Cercopithecine herpesvirus 1 (B virus), Simian-T-lymphotropic virus (STLV), respiratory syncytial virus (RSV), tuberculosis (TB), and dewormed. After experimental infection, animals are isolation housed, to avoid SIV superinfection, in metal wire cages at an ambient temperature of 72 ± e F. RMs are fed a diet consisting of jumbo biscuits supplemented with 15% protein; half an orange per day; and produce enrichment five times per week. All procedures are approved by the Emory University Institutional Animal Care and Use Committee (IACUC) and animal care facilities are accredited by the U.S. Department of Agriculture (USDA) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.
All RMs were infected intravenously with 1000 TCID50 of SIVmac251 ( Figure 1A ). Approximately 7 weeks post-infection, all animals initiated an antiretroviral therapy (ART) regimen consisting of tenofovir (PMPA; 20-25 mg/kg/d, s.c.), emtricitabine (FTC; 30-50 mg/kg/d, s.c.), raltegravir (100-150 mg/bid, oral), darunavir (400-700 mg/bid, oral), and ritonavir (50 mg/bid, oral), which was maintained daily for the duration of the study (Table S1 ). To enhance control of viral load, this regimen was intensified with the addition of maraviroc (100-150 mg/bid, oral) 21-24 weeks after ART initiation in 7 RMs. Animals remained on ART until plasma viremia was undetectable (limit of detection: 60 copies viral RNA/mL) for at least 3 months (5.0 ± 1.4 months from first undetectable plasma viral load). Following persistent viral suppression, animals underwent elective necropsy, with the exception of one RM who exhibited rapid disease progression and had to be sacrificed following ten days of ART (RKa13 ; Table S1 ). Longitudinal analysis accounts for all RMs, while cell-associated DNA and RNA quantitation includes only the 9 animals which reached study completion.
Sample collection and processing
Blood, lymph node (LN), and rectal biopsies (Gut) were performed longitudinally and at necropsy. Blood samples were used for a complete blood count and routine chemical analysis, and plasma was separated by centrifugation within 1 hr of phlebotomy. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density gradient centrifugation. To obtain rectal biopsy punches, an anoscope was placed a short distance into the rectum for the collection of up to 20 pinch biopsies with biopsy forceps. Gut-derived lymphocytes were digested with 1 mg/mL collagenase for 2 hours at 37 C, and then passed through a 70-mm cell strainer to remove residual tissue fragments. Intestinal samples, which included segments of the rectum, colon, ileum, and jejunum, were collected from necropsied animals into RPMI 1640 medium supplemented with 10%FBS, 100 IU/mL penicillin, and 100 mg/mL streptomycin. Intestinal samples were cut into small pieces, and digested with 1 mg/mL collagenase by shaking for 2 hr at 37 C. To enrich for lymphocytes, filtered samples were layered over a discontinuous Percoll density gradient (GE Life Sciences), centrifuged and washed in PBS prior to staining and/or sorting. For LN biopsies, the skin over the axillary or inguinal region was clipped and surgically prepped. An incision was then made in the skin over the LN, which was exposed by blunt dissection and excised over clamps. LNs were then homogenized and passed through a 70-um cell strainer to isolate lymphocytes. All samples were processed, fixed (1% paraformaldehyde), and analyzed within 24 hours of collection.
Determination of viral load RNA Quantitative real-time RT-PCR was performed to determine SIV plasma viral load as previously described (Amara et al., 2001) .
Flow cytometric analysis
Fourteen-parameter flow cytometric analysis was performed on peripheral blood, LN, and gut-derived cells according to standard procedures using a panel of monoclonal antibodies that we and others have shown to be cross-reactive with RMs (Micci et al., 2015) . The following antibodies were used at predetermined optimal concentrations: anti-CD3-APC-Cy7 (clone SP34-2), anti-Ki-67-Alexa700 (clone B56), anti-CD95-PE-Cy5 (clone DX2), anti-CCR7-PE-Cy7 (clone 3D12), anti-CTLA-4-BV421 (clone BNI3), all from BD Biosciences; anti-CD4-BV605 (clone OKT4), anti-PD-1-PE-Cy7 (clone EH12.2H7), anti-CD95-BV605 (clone DX2), anti-CD25-BV711 (clone BC96), and anti-FoxP3-APC (clone 150D) from Biolegend; anti-CD8-Qdot705 (clone 3B5) and Aqua Live/Dead amine dye-AmCyan from Invitrogen; anti-CD28-ECD (clone CD28.2) from Beckman Coulter; anti-CD127-PECy5 (clone eBioRDR5) and anti-CXCR5-PerCp-Cy5.5 (clone MU5UBEE) from eBioscience; and anti-TIM-3-PE (clone 344823) from R&D. To determine the ex vivo phenotype of CTLA-4 + CD4 + T cells, CTLA-4 staining has been performed intracellularly in unstimulated T cells. To detect the expression of CTLA-4 on the cell surface with improved sensitivity, as required for sorting and viral reservoir measurements, mononuclear cells were stimulated for 3 hours at 37 C with phorbol myristate acetate (PMA; 80 ng/mL) and ionomycin (500 ng/mL), and CTLA-4 antibody was added to the stimulation media at the start of stimulation. To detect the expression of FoxP3 intracellularly, mononuclear cells were fixed and permeabilized with FoxP3 Fix/Perm solution (Tonbo), and subsequently stained intracellularly for FoxP3. Flow cytometric acquisition was performed on at least 100,000 CD3 + T cells on an LSRII cytometer driven by the FACS DiVa software, or at least 10,000 CD3 + T cells for gut-derived cells. The data acquired were analyzed using FlowJo software (version 9.8.5; TreeStar).
Flow cytometry cell sorting
Mononuclear cells isolated from blood, LN, spleen, and pooled gut mucosal tissues (including right and left colon, ileum, jejunum, and rectum) were stimulated for 3 hours with PMA and Ionomycin, as described above, during which anti-CTLA-4 antibody was added with the stimulation media, and subsequently stained with anti-CD3, anti-CD4, anti-CD8, anti-CD28, anti-CD95, anti-PD-1, anti-CTLA-4 and anti-TIM-3. Memory CD4 + T cells were then sorted based on their expression of PD-1, CTLA-4, and TIM-3 using a FACS AriaII (BD Biosciences). With the exception of gut mucosal tissues, memory CD4 + T cells sorted at necropsy were first separated into PD-1 positive and negative populations. These subsets were then sorted into four subsets based on their expression of CTLA-4 and TIM-3. Memory CD4 + T cells sorted during the study, and from gut mucosal tissues at necropsy, were sorted by their PD-1 and CTLA-4 expression alone, due to a lower quantity of starting material. Sorted CD4 + T cell subsets were on average > 96% pure as determined by post-sorting flow cytometry analysis.
Quantitation of cell-associated SIV DNA and RNA Cellular DNA and RNA were extracted from at least 10,000 sorted memory CD4 + T cells lysed in RLT Plus buffer (QIAGEN) and isolated using the AllPrep DNA/RNA Mini Kit (QIAGEN) per the manufacturer's instructions. cDNA was synthesized from extracted RNA, and quantification of SIVmac GAG DNA and cDNA was performed on samples using the QX100 TM Droplet Digital TM PCR system (Bio-rad). Total SIV DNA and RNA were quantified for these samples using SIVmac GAG primers and probes, and normalized to the GAPDH gene (see Key Resource Table) . Data was analyzed using the Quantasoft analysis software 1.3.2.0 (Bio-rad).
Intracellular cytokine staining
The production of IL-21 by Co-IR-expressing subsets was determined by examining the frequency of memory CD4 + T cells that produced IL-21 following a 3 hour in vitro stimulation with PMA and ionomycin (see above). PBMC-and LN-derived cells, isolated as described above, were resuspended to 3x10 6 cells/mL in complete RPMI 1640 media containing PMA, ionomycin, Brefeldin A, and BD Golgistop. Cells were then incubated at 37 C for 3 hours. Stimulation was stopped by washing cells with PBS. Following a 30 min surface stain, cells were fixed and permeabilized prior to staining intracellularly with anti-IL-21-PE (clone 3A3-N2.1; BD Biosciences) for 45 min at room temperature. Following staining, cells were washed and fixed in PBS containing 1% paraformaldehyde (PFA), and acquired on a BD LSRII cytometer.
SIV DNA in situ hybridization and immunofluorescent detection for confocal phenotypic analysis Viral DNA detection (DNAscope) was performed and validated as described previously (Deleage et al., 2016) . Briefly, following HIER (Pretreat 2 step; ACD) and proteinase digestion (Pretreat 3 step, ACD), the slides were incubated overnight (between 18-21 hours) at 40 C with HIV clade B sense probe or SIVmac239 sense probe. Amplification steps were performed according to the ACD protocol with the exception that all wash steps used a 0.5X wash buffer. Amplification reagents from the RNAscope 2.5 HD Brown Detection Kits were used for Tyramide Signal Amplification (TSA) Plus Cy3.5 immunofluorescence detection. We combined DNAscope detection (TSA Plus Cy3.5) with immunofluorescence incubating overnight at RT: rabbit polyclonal anti-PD-1 (1:200; Cat#HPA035981; SIGMA) and goat polyclonal anti-hCTLA-4 (1:200; Cat#AF-386-PB; R&D Systems). Slides were washed, incubated with secondary donkey anti-goat IgG-Alexa 488 and anti-rabbit IgG-Alexa 647 (all from Molecular Probes/ThermoFisher Scientific) for 1 hr at room temperature, and washed 2 times for 5 min in TBS + tween (0.05% v/v). To decrease auto-fluorescence, the tissues were incubated with Sudan Black solution [0.1% in 80% ethanol (ENG Scientific, Inc.) in 1x TBS]; for 20-30 min at room temperature and then washed, counterstained with DAPI (RTU; ACD) for 10 min, washed, and coverslipped with #1.5 GOLD SEALÒ cover glass (EMS) using ProlongÒ Gold reagent (Invitrogen).
To quantify the number of vDNA + cells and proportion that were PD-1 
Determination of replication competent and infectious virus in memory CD4 + T cells during ART
Cryopreserved LN cells from ART-treated, SIV-infected RMs were sorted to high purity into memory CD4 + T cell subsets based on their expression of CTLA-4 and PD-1. Due to limited cryopreserved LN cell numbers, 7 RM LN were sorted: 3 SIVmac251-infected RM followed in this study (RJf13, 108 days with undetectable plasma viremia; RLr10, 206 days undetectable; RWo10, 153 days undetectable), and 4 SIVmac239-infected RMs from another study (RPu12, 106 days undetectable; RLm12, 165 days undetectable; RGv10, 136 days undetectable; RTb12, 106 days undetectable). Purified CTLA-4 and PD-1-expressing memory CD4 + T cell subsets were stimulated for 6 hours with anti-CD3 and anti-CD28, and then co-cultured at a 1:1 ratio with the CEMx174 cell line, a fusion product between the human CEM T cell line with human B cell line 721.174 (NIH AIDS Research and Reference Reagent Program), with starting cell numbers ranging from 1.5 to 2.5 3 10 5 memory CD4 + T cells per well. Co-cultures were maintained in complete RPMI 1640 media supplemented with 10%FBS, 100 IU/mL penicillin, 100 ug/mL streptomycin and IL-2 (100 U/mL) at 37 C under 5% CO 2 . Cells were split and fed with fresh media containing IL-2 weekly (days 14, 21, 28, and 35), and harvested at days 14 and 35. The presence of replication competent virus was detected by positive SIV GAG p27 expression within the CD4 + cell population, using flow cytometry (Fukazawa et al., 2015; Micci et al., 2015) , and by quantifying SIVGAG RNA in the supernatant using qRT-PCR (see Experimental Procedures above). 200 mL of clarified co-culture supernatant at day 35 from the wells containing the CTLA-4 + PD-1 -was used to spike 5 3 10 5 uninfected CEMx174 cells. Only uninfected (negative control) or in vitro SIV-infected (positive control) CEMx174 cells were also used. Cultures were maintained for 7 days under the same conditions as the co-culture (see above) and the presence of replication competent virus was detected by positive SIV GAG p27 expression within the CD4 + T cell population, using flow cytometry.
Assessment of STAT5 phosphorylation
The amount of phosphorylated STAT5 within CTLA-4 and PD-1-expressing subsets was measured by phospho-flow cytometry in ART-treated, SIV-infected RM LN samples, both ex vivo and following a three hour in vitro stimulation with PMA and ionomycin (see above). A minimum of 10 6 cells were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD20 (clone 2H7; BD Biosciences), anti-PD-1, anti-CTLA-4 and a viability stain (Live/Dead Fixable Aqua, Invitrogen) for 20 min at 4 C. Samples were fixed for 10 min with 4% PFA at 37 C, permeabilized for 20 min with Perm Buffer III (BD Biosciences) on ice, and then stained intracellularly with anti-pSTAT5 (clone 47/Stat5(pY694); BD Biosciences) for 30 min at room temperature. Following staining, cells were washed and fixed in 1% PFA, and acquired on a BD LSR Fortessa.
QUANTIFICATION AND STATISTICAL ANALYSIS
Repeated-measures analyses for each memory CD4 + T cell subset outcome were performed with a means model via the SAS MIXED Procedure (version 9.4; SAS Institute, Cary, NC), providing separate estimates of the means by time on study. The statistical model included one predictor (time on study) with up to 17 categorical levels, and was fit separately for each anatomic location. A compound-symmetric variance-covariance form in repeated-measurements was assumed for each outcome and robust estimates of the standard errors of parameters were used to perform statistical tests and construct 95% confidence intervals. The model-based means are unbiased with unbalanced and missing data, so long as the missing data was non-informative (missing at random, MAR). Three specific statistical tests were done within the framework of the mixed effects linear model for each anatomic location. All statistical tests were two-sided and unadjusted for multiple comparisons. A p value % 0.05 was considered statistically significant for each of the specific statistical comparisons. Results from these studies also focused on the magnitude of the differences for each outcome as reflected by confidence intervals, consistency of findings, and biological significance. Similar repeated-measures analyses were performed for log 10 SIV DNA over time by anatomic location. Comparisons of cell-associated DNA were calculated using t tests and Mann-Whitney U tests, respectively, as determined by sample distribution (normal or nonnormal). DNA measurements were excluded for samples in which < 10,000 cells were sorted and values fell outside the assay limit of detection. Longitudinal comparisons of cell-associated DNA were calculated using paired t tests. Pearson product-moment correlation coefficients were used to estimate linear associations for SIV DNA data. Data showing continuous outcomes are represented as mean ± SEM. Analyses of SIV DNA were conducted using GraphPad Prism 6.0.
